Loading stock data…
FBLG
$0.93-0.08 (-7.92%)
After Hours$0.93+0.00 (+0.00%)· Last close Jun 9
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
FibroBiologics, Inc. in the Healthcare sector is trading at $0.96 with a market capitalization of $5M. Wall Street consensus targets $13.50 (2 analysts), implying a +1309.2% move over the next 12 months. The stock is currently near its 52-week low of $0.95, remaining 83.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +1309.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$0.93
Potential Downside
0%
Whystock Fair Value$0.93
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$13.50+1351.6%
Range$8.00 – $19.00
Fundamentals
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has compl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.99M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.15
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-718.46%
Volume
Today's trading volume
136,112
Recent News
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial
FibroBiologics Inc. (NASDAQ:FBLG) on Wednesday announced that it has enrolled and dosed the first patients in its Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers (DFUs). FibroBiologics Does First Patients In CYWC628 Trial FibroBiologics said it has dosed the first patients in the CYWC628 Phase 1/2 clinical trial. The CYWC628 fibroblast-based therapy targets diabetic foot ulcers, a condition that affects millions of patients worldwide and currently lacks effe
Is FibroBiologics, Inc. (FBLG) Advancing Toward a Breakthrough Psoriasis Treatment With CYPS317 Data?
We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. FibroBiologics, Inc. (NASDAQ:FBLG) is among the most popular penny stocks. TheFly reported on May 22 that FBLG released preclinical findings from its CYPS317 psoriasis program at the Society for Investigative Dermatology 2026 Annual Meeting. The company reported that […]